Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent protected DETERx formulation platform for the treatment of chronic pain. The DETERx oral drug delivery technology provides extended release delivery, unique tamper resistant properties, and flexible dose administration options.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/22/12 | $22,500,000 | Series B |
Boston Millennia Partners Frazier Healthcare | undisclosed |
| 03/11/15 | $50,000,000 |
Adage Capital Management Aperture Venture Partners Boston Millennia Partners Eventide Asset Management Frazier Healthcare Longitude Capital RA Capital Rock Springs Capital TPG Biotech | undisclosed |
